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opment. Although existing biomarkers have proved extremely useful for enrichment of subjects in
clinical trials, there is a clear need to develop novel biomarkers that are minimally invasive and
that more broadly characterize underlying pathogenic mechanisms, including neurodegeneration,
neuroinflammation, and synaptic dysfunction. These may include blood-based assays and new neu-
ropsychological testing protocols, as well as novel ligands for positron emission tomography imag-
ing, and advanced magnetic resonance imaging methodologies. In addition, there is a need for
biomarkers that can serve as theragnostic markers of response to treatment. Standardization remains
a challenge, although international consortia have made substantial progress in this area and provide
lessons for future standardization efforts.
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A biomarker is a characteristic that can be objectively
measured and evaluated as an indicator of a normal or path-uthor. Tel.: 146-(0)-40-33-50-36; Fax: 146-(0)-40-
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).ologic process, or as a measure of response to therapy [1]
(Biomarker Working Group 2001). Biomarker research has
revolutionized the understanding of Alzheimer’s disease
(AD) and is in the process of transforming the design of
AD clinical trials. Until recently, AD was only imprecisely
diagnosed in life using clinical assessments during the de-
mentia stage or at time of death by neuropathology. None-
theless, substantial progress over the past decades inimer’s Association. This is an open access article under the CC BY-NC-ND
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markers has shown that AD brain changes can be detected
and used for diagnosis and prognosis of AD [2,3].
As these biomarkers have been included in observational
studies of AD, better understanding of the biochemical and
pathologic changes of AD has occurred. This has led to
confirmation of the hypothesis [4,5] that AD is a disease
progressing from preclinical to early and then late clinical
stages, and which is now emphasized in novel research
diagnostic criteria incorporating biomarkers [6]. Previously,
drug developers focused on the dementia stage of the disease.
This has now radically changed as clinical trials move toward
earlier stages of AD, before extensive neurodegeneration has
occurred [7–9], and even to secondary prevention before
symptom onset [10–12], when disease-modifying treatments
are likely to have maximal effect. Biomarkers play a key role
in the design of these trials, both for inclusion of subjects with
AD pathology and to track biological effects of drugs. Yet
even though it is a widely held belief that AD biomarkers
can be used for diagnosis, prognosis/prediction, and to
monitor the effects of therapy [1,13], in the absence of an
effective treatment to slow progression of AD (and the
underlying pathogenic processes), the link between
biomarkers and effect on disease cannot be established.
Data from many studies all over the world, including the
Alzheimer’s Disease Neuroimaging Initiative [14], its
worldwide partners (WW-ADNI) [15], and the Dominantly
Inherited Alzheimer’s Network (DIAN) [16], have done
much to delineate the temporal changes in biomarkers
over time and clarify their relationship to cognition and
function. Yet despite the field’s growing acceptance of the
need for biomarkers in drug development, the belief that bio-
markers could improve clinical trial design and the success
of those trials was shaken by recent mixed clinical trial re-
sults. The phase III bapineuzumab trial, in particular, went
forward in part based on findings in phase II studies that
showed modest reductions in brain amyloid [17], and CSF
phosphorylated tau (P-tau) concentrations [18]. The pre-
sumption that these biomarker effects represented a clini-
cally relevant treatment effect, however, was called into
question when no clinical benefit was found in the phase
III trials, despite hints that biomarkers were impacted by
therapy [19]. The phase III results for solanezumab also
did not provide statistically significant effects for coprimary
outcomes; however, planned secondary analyses were
consistent with clinical benefit of solanezumab in patients
with mild AD dementia without evidence of an impact of
solanezumab on brain amyloid burden, downstream neuro-
degeneration markers of CSF tau proteins or brain volume,
but with an increase in total CSF Ab42 and Ab40 [20].
In this setting, the Alzheimer’s Association Research
Roundtable convened a meeting in May, 2014 to explore
the extent to which biomarkers have furthered our under-
standing of the disease, supported drug development, and
improved the care of patients; and more importantly, to iden-
tify what needs to be done to realize their full potential. Canbiomarkers indeed provide answers to guide future trials to-
ward more successful outcomes? The Roundtable examined
evidence to support this premise, identified unanswered
questions, and explored areas of potential collaboration in
precompetitive space among key stakeholders that might
expedite this effort.2. Biomarkers as enrichment tools for clinical trials
Further critical examination of the bapineuzumab and sol-
anezumab studies suggested several possible reasons for the
negative trial results. One contributing factor is that some of
the enrolled trial subjects may not have AD [21]. Clinical
criteria for patient inclusion in each program resulted in study
populations with a significant percentage of participants
without evidence of brain amyloid by positron emission to-
mography (PET;w7 and 36% amyloid negative in apolipo-
protein E (APOE) 34 carriers and noncarriers, respectively)
[22]. Using amyloid biomarkers to enrich for trial subjects
who are amyloid-positive—and thus presumably on the AD
trajectory—may improve the ability of future trials to detect
a treatment effect especially for anti-amyloid therapies.
Indeed, data from several studies have shown that among
cognitively normal elderly, those who are amyloid-positive
are at greater risk of decline compared with those who are
amyloid-negative [6,23–26]. In the placebo arms of both
the bapineuzumab and solanezumab studies, which
enrolled subjects with mild-to-moderate AD, amyloid-
positive subjects had significant decline on both cognitive
and functional measures, whereas the amyloid-negative sub-
jects did not [22]. Importantly, the effect of amyloid pathol-
ogy on longitudinal memory declinemay be greater inAPOE
34 carriers compared with APOE 34-noncarriers [27].
Disease severity may be another factor that contributed to
the negative trial results. In comparison with subjects with
mild disease, those with more advanced clinical disease
may have far more advanced neurodegeneration. The
modest impact of treatment on the underlying pathology
and markers of the pathology may not be sufficient to trans-
late to a clinical benefit. In the bapineuzumab studies, even
individuals with the largest reported decrease in amyloid still
had elevated values in the AD range and although significant
treatment differences were observed between bapineuzumab
and placebo, the change from baseline values in the bapineu-
zumab groups ranged w0%–10% (with reductions in the
CSF P-tau concentration and inhibited further accumulation
of brain amyloid by PET) [17–19]. Finally, it is possible that
the presence of copathologies (for example tau, vascular,
Lewy body, or transactive response DNA binding protein
43 [TDP-43] pathology) may influence cognitive
trajectories independent of amyloid pathology [28,29] and
impact trial results.
Many trials currently underway or planned are therefore
enrolling subjects in earlier stages of disease and using am-
yloid biomarkers, either amyloid PET imaging or CSFAb42
levels, to enrich for trial subjects thought more likely to
Table 1
Current ongoing or planned AD clinical trials sponsored by pharmaceutical industry as reported at the Research Roundtable (May 2014)
A4 (Lilly) AstraZeneca Biogen Idec Eisai Eli Lilly Merck Merck pAD Roche
Takeda
(TOMMORROW)
Phase/
duration
3.3 y 2.0 y Ph1b/2.0 y Ph2b/1.5 y Ph3/1.5 y Ph3/1.5 y Ph3/1.5 y Ph3/2.0 y Ph3/2.0 y
Population Amyloid1;
65–85 yo;
normal
cognition
Amyloid1;
55–85 yo;
mild and
pAD
Amyloid1;
mild and
pAD
Amyloid1;
early AD
(mild and
pAD)
Amyloid1;
mild AD
55–85 yo;
MtM AD
Amyloid1
50–85
yo; pAD
Amyloid1;
(1) pAD
50–85
yo; (2)
mild AD,
50–90 yo
Preclinical AD
(asymptomatic
at risk for
MCI due
to AD)
Sample Size 10001 15001 w160 Adaptive; up
to 800
2100 1960 1500 (1) 700;
(2) 1000
3800
Regions USA, Canada,
Australia
Global USA North
America,
EU
North
America,
EU, Japan
Global Global Global North America,
EU, Russia,
Australia
Primary
Biomarker
Screen
Amyloid PET
(Amyvid)
Amyloid PET
or CSF
Ab42
Amyloid
PET
(Amyvid)
Amyloid
PET
Amyloid PET
(Amyvid1)
or CSF Ab42
None Amyloid PET
(Vizamyl)
CSF Ab42 TOMM40
rs10524523,
APOE,
age (Risk
algorithm)
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; PET, positron emission tomography; CSF, cerebrospinal fluid; y, years; yo, years
old; pAD, profromal AD; MtM, mild-to-moderate.
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(Table 1). Only the TOMMORROW trial of the mitochon-
drial targeting agent pioglitazone (an approved antidiabetic
prescription drug) uses a genetic enrichment strategy based
on TOMM40 and APOE genotype and age to identify normal
individuals at risk of developing mild cognitive impairment
over a 5-year period.
Several considerations are raised with the use of amyloid
PET imaging or CSFAb42 as a screening tool and enrichment
criterion to be addressed for trials of anti-amyloid therapies:
 How practical is it to require amyloid positivity by PET
or CSF as an inclusion criterion in a large (global) trial?
 Is there an advantage of one amyloid test over the other
(CSF vs. PET)?
 Is it possible to establish standard cutoffs for PET or
CSF amyloid assessments to differentiate between
normal and pathologic state?
 Will standard cutoffs differ based on the stage of dis-
ease, for example as discussed in Lim et al. (2015)
[30]?
 Are quantitative PET reads required, or is a visual read
sufficient?
 Are the different radiotracers interchangeable, or is it
necessary for all screens to be performed using a single
radiotracer?
 Are different CSF assays interchangeable? Can novel
development of reference standard procedures and ma-
terials overcome variability problems?
 How can between-site variability for PET scans or CSF
biomarker measurements be overcome?
 If a subject has had a previous amyloid biomarker mea-
surement that indicates amyloid-positivity, can this his-
torical data be used to satisfy the inclusion criterion? What are the labeling implications of having amyloid
positivity as an eligibility criterion? Will the amyloid
tests be considered companion diagnostics?3. Supporting a disease modification claim with
biomarkers
In the USFood andDrugAdministration (FDA) draft guid-
ance on developing drugs for early stage disease, disease
modification is defined as a “direct effect on the underlying
disease pathophysiology.” The guidance goes on to consider
the possibility “that a claim of disease modification could
be supported by evidence of a meaningful effect on a
biomarker in combination with a clinical benefit” [31]. In
its Guideline onMedicinal Products for the Treatment of Alz-
heimer’s Disease and Other Dementias, the European Medi-
cines Agency defines disease modification as “slowing or
arrest of symptom progression of the dementing process,”
and like FDA, suggests that “Ideally proof of a disease modi-
fying effect would require demonstration of clinically relevant
changes. [and] supportive evidence for a change in the un-
derlying disease process based on biological markers,” [32].
Based on research from the past several decades andmore
recent data from larger observational studies such as ADNI,
Australian Imaging, Biomarker & Lifestyle Flagship Study
of Ageing (AIBL), and DIAN, a consensus is emerging
that AD begins decades before dementia onset [5,33] and
is heralded by successive changes in markers of the
underlying disease processes [4,34]. Several biomarkers
are known to be relevant in AD and have been studied
intensely [35–38]. Hippocampal atrophy rates show high
correlation with cognitive change [39]. However, by its
very nature, magnetic resonance imaging (MRI) does not
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not only neuron loss but other neurodegeneration-associated
events including loss of axonal tracts/dendrites, loss of other
cell types (e.g. astrocytes, microglia), inflammatory pro-
cesses, and associated alterations of interstitial fluid volume
[37,40].
Other available biomarkers that reflect pathogenic pro-
cesses of the disease include CSF levels of total tau (T-tau)
and P-tau, which are related to cortical axonal degeneration
and tangle pathology [41,42]; CSF Ab42 and amyloid PET
imaging, which correlate negatively and positively,
respectively, with amyloid plaque load at autopsy [43]; and
fludeoxyglucose (FDG)-PET, a measure of glucose meta-
bolism, which may partly reflect synaptic dysfunction [44].
However, even if a biomarker has been shown to be rele-
vant to AD, its utility as a theragnostic biomarker is not guar-
anteed. For example, although biomarkers such asCSFT-tau/
P-tau and volumetric MRI are clearly affected in observa-
tional studies of AD, the effect of a disease-modifying ther-
apy on these biomarkers may be influenced by multiple
factors, such as the mechanism of action of the therapeutic
or related disease processes. Thus, each candidate biomarker
must be evaluated empirically for response to therapy.
For example, although both bapineuzumab and solanezu-
mab are monoclonal antibodies against the Ab42 peptide, there
were differences in which AD relevant biomarkers responded
to treatment. These differences may be due to differences in
binding properties of the antibodies, i.e., soluble versus aggre-
gated amyloid [45–47], and illustrate the fact that not all AD
relevant biomarkers may serve as theragnostic biomarkers in
all trials and that multiple factors will influence their utility.
An additional point is that the observed biomarker changes
in response to therapy were small to modest and not
accompanied by a slowing of decline in cognition and, thus,
do not support a disease-modifying effect. To date, it is un-
known to what degree treatment-induced change in a
biomarker would be sufficient to test the underlying therapeu-
tic hypothesis. Thus, it is premature to judge the theragnostic
value of any biomarker that has, to date, only been modestly
perturbed by any treatment.
Furthermore, differentiation between utility as bio-
markers of target engagement versus theragnostic response
may be needed. For an anti-amyloid treatment, an amyloid
marker may be used to assess target engagement, but use
of a downstream neurodegenerative marker, such as a
marker of tau biology, may be required for therapeutic moni-
toring. Similarly, for a therapeutic agent targeting tau pathol-
ogy, measurement of CSF tau levels or tau PET imaging
might prove useful for trial enrichment and/or target engage-
ment, but other markers might be required to characterize
treatment effect on the downstream pathology. Thus, novel
biomarkers need to be discovered and/or developed that
can characterize other aspects of the neurodegenerative pro-
cess. Importantly, when analyzing biomarkers, whether new
or old, longitudinal studies are needed that provide evidence
of change over time.4. Standardization
For biomarkers to be used in clinical trials, standardiza-
tion of sample and data collection protocols and analytical
methods is essential. Particularly, the ability to combine
data across time and study sites is crucial. Perhaps more
importantly, the ability to reduce or control variability intro-
duced by the measurement methodology improves the po-
tential to detect and measure biological changes resulting
from therapeutic intervention. Standardization can promote
comparison across studies and ease the transition from
research use to use in a regulatory environment (pivotal clin-
ical trials) and in clinical practice. Here, we will review stan-
dardization efforts for CSF and imaging biomarkers.
Currently there are several commercially available assays
tomeasure CSF biomarkers (Ab42, P-tau, and T-tau), some of
which have Conformite Europeenne (CE)-marking in Eu-
rope, but none of which have been cleared by FDA. Although
performance of the different assays to differentiate between
normal and pathologic is similar, the absolute values reported
by them for any particular analyte are different [48]. There
are several different possible sources of preanalytical and
analytical variability of CSF biomarker measurements [49].
Standardization efforts for CSF biomarkers to address prea-
nalytical and analytical issues have been initiated by the Alz-
heimer’s Association (AA) under the Global Biomarkers
Standardization Consortium [50]. To date, the lack of stan-
dardization across available assays has required use of
assay/laboratory-specific cut points to convert numerical
data from eachmethod into clinically meaningful categorical
results. The standardization programs described previously
aim to enable a universally acceptable cut point to differen-
tiate normal from pathologic states using CSF biomarker re-
sults generated across time, assays, and laboratories.
Quantitative analyses from amyloid PET images acquired
frommulticenter studies require standardization of protocols
to reduce measurement variability and error with attention
and emphasis on different aspects when conducting cross-
sectional or longitudinal comparisons. Standardization
efforts involve three main areas of focus: scan acquisition,
image processing, and image analyses. A comprehensive re-
view of these topics is recently detailed [51]. With the intro-
duction of multiple tracers, each of which with slightly
different characteristics, comparison of results across studies
has become even more challenging. The Centiloid Project
proposes to calibrate all amyloid imaging tracers according
to a unified and standardized numerical scale [52] and would
theoretically allow results from studies using different
tracers to be combined and compared.
Standardization of methods for structural MRI measures
of hippocampal volume has been undertaken by the Euro-
pean Alzheimer’s Disease Consortium (EADC)-ADNI Hip-
pocampal Harmonization Protocol project, with funding
from the AA and six medical device, diagnostics, and phar-
maceutical companies. This project has developed a harmo-
nized protocol for estimating hippocampal volume through
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to acquisition of images (e.g., different manufacturers, se-
quences, positioning of the patient), variability in algo-
rithms, readers, and patient characteristics.5. Pattern and time course of biomarker changes in AD
The hypothetical model of dynamic biomarkers proposed
by Jack et al. [4], in which a gradual, ordered, and successive
alteration in AD biomarkers, beginning with amyloid pathol-
ogy, then tauopathy, and later neurodegeneration, preceding
clinical symptoms, and eventual dementia, recapitulates the
key tenets of the amyloid cascade hypothesis [54,55].
Although recent data support many aspects of this model
[2,16,26,56–58], some do not and the model has been
updated accordingly [34]. The main impetus for the change
is due to the evidence that medial temporal lobe tau pathology
occurs in normal aging independent of amyloid [59,60].
Furthermore, data support that amyloidosis and
neurodegeneration (tauopathy) may initiate independently
but that abnormal (high levels) amyloid and tau interact with
amyloid accelerating the downstream neurodegeneration
[61]. Thus, although the model provides a framework for the
general trend of biomarker changes at a population level,
more work is needed to understand possible individual differ-
ences in the ordering of biomarker changes [34].6. Novel biomarkers
Roundtable participants agree on the need for additional
novel biomarkers for other aspects of AD pathophysiology,
including neuroinflammation, neurodegeneration, synaptic
dysfunction, and other associated neuropathologies (e.g.,
a-synuclein) and comorbid conditions. Although CSF bio-
markers provide the most direct biochemical access to the
brain with few confounds from other organs [62], blood-
based biomarkers are desired for large-scale screening.
Novel imaging biomarkers, including tau imaging [63–67],
advanced MRI methodologies [68,69], and new
neuropsychological testing protocols, have also shown
promise in providing a more comprehensive picture of the
progression of dementing diseases [70–73].
A number of novel CSF biomarkers have been identified
for staging and potentially tracking AD, including visinin-
like protein (VILIP)-1 [74,75], YKL-40 [76] and heart-
type fatty acid binding protein (HFABP) [77], among others.
Novel biomarkers may also be helpful in differentiating AD
patients with copathologies.
Ideally, to enrich studies for subjects who are likely to
have AD pathology, low cost and minimally invasive bio-
markers optimized for sensitivity may be part of a screening
funnel that can reduce the number of subjects to be evaluated
by a more costly/invasive amyloid test (PETor CSF). Blood-
based assays are currently in development for a variety of an-
alytes, including various species of Ab and tau, a-synuclein,and TDP-43. Furthermore, proteomic studies have identified
hundreds of potential markers of inflammation, oxidative
stress, mitochondrial dysfunction, neuronal and microvas-
cular injury, and metabolic processes. Investigators have
constructed several multianalyte panels to detect, classify,
and predict disease progression, although these findings
require replication [78–80]. Other approaches such as
microRNA and plasma exosome analyses are also being
investigated for utility in identifying individuals likely to
have AD pathology [81–83]. An international working
group of experts in the field has been formed to address
the challenges that have hampered development of blood-
based biomarkers [84].
7. Conclusion and steps forward
The Roundtable concluded that more longitudinal studies
on biomarker trajectories, specifically evaluating change in
individuals, are needed to confirm or modify the findings of
cross-sectional studies that have dominated the field to this
point. In addition, therewaswidespread support for increased
effort and focus on studies linking neuropathology to bio-
markers, and a suggestion that additional public-private
funding may be needed to achieve this. Specifically, it would
be valuable to assess and compare postmortem samples from
patients involved in different clinical trials. Finally, novel
biomarkers that reflect other disease processes downstream
of the initiating AD pathologies would not only increase
our understanding of AD but can potentially provide needed
tools for next-generation AD therapies in development.RESEARCH IN CONTEXT
1. Systematic review: There have been many reviews
on Alzheimer’s disease (AD) biomarkers in the last
5 years, but this article is unique that the Alzheimer’s
Association Research Roundtable provides an unpar-
alleled forum in which the leading experts on Alz-
heimer’s disease from pharmaceutical industry,
nonprofit organizations, and governmental organiza-
tions can collaborate on moving the field forward by
identifying areas of research that are most critical to
achieve a successful next generation AD therapeutic.
2. Interpretation: This article summarizes the foremost
areas of work in the view of industry drug developers
to achieve a successful nextgenerationAD therapeutic.
3. Future directions: Continuedwork in theAlzheimer’s
Association Research Roundtable (AARR) precom-
petitive space will allow optimization of resource
use across different sectors.
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